TRK inhibitor (next generation) · small molecule
selitrectinib
0 active trials, targeting TRK. Not approved for any biomarker on marked.bio yet.
Also known as LOXO-195, BAY 2731954.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| NTRK1/2/3 fusion | 0 | 1 | – |
Trials
0 of 1 trials shown
-
A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer
a) a documented NTRK fusion and a clinical history of relapse following a response to a prior TRK inhibitor
NTRK1/2/3 fusionSolid Tumors Harboring NTRK Fusion
No trials match these filters.